NEW YORK (GenomeWeb) – The American College of Medical Genetics and Genomics is working on a first update to its gene list for reporting secondary findings from exome or genome sequence data with the aim of finalizing the revisions by the end of the year, GenomeWeb has learned.

In addition, an ACMG committee tasked with the update has been looking into how pharmacogenomics genes can be added to the list without unduly burdening clinical labs reporting the results, but PGx genes will only be implemented in future updates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.